SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3.07 |
| Enterprise Value ($M) | -1.58 |
| Book Value ($M) | 16.33 |
| Book Value / Share | 7.23 |
| Price / Book | 0.19 |
| NCAV ($M) | 13.95 |
| NCAV / Share | 6.18 |
| Price / NCAV | 0.22 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.46 |
| Return on Assets (ROA) | -0.52 |
| Return on Equity (ROE) | -0.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.42 |
| Current Ratio | 7.42 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16.12 |
| Assets | 18.50 |
| Liabilities | 2.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -6.28 |
| Net Income | -7.52 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.88 |
| Cash from Investing | -1.11 |
| Cash from Financing | 8.79 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Baharaff Allen | 2.60 | -86.10 | |
| 13G/A | CVI Investments, Inc. | 9.90 | -59.68 | |
| 13G/A | Otsuka Masaya | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 7,329 | 28,706 | 25.53 | |
| 10,943 | 42,533 | 25.73 | |
| 69,586 | 168,534 | 41.29 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GALT – Galectin Therapeutics Inc. | GDTC – CytoMed Therapeutics Limited |
| GELS – Gelteq Limited | GLSI – Greenwich LifeSciences, Inc. |
| GLTO – Galecto, Inc. |
Financial data and stock pages provided by
Fintel.io